Prot #2102-HEM-101: A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

Project: Research project

Project Details

StatusActive
Effective start/end date12/16/1612/16/22

Funding

  • Novella Clinical, LLC (Prot# 2102-HEM-101)
  • FORMA Therapeutics, Inc. (Prot# 2102-HEM-101)